Evidence map›Paper›PMID 25096606›Full record

ArticleAnnals of oncology : official journal of the European Society for Medical Oncology2014

Chronic natural killer lymphoproliferative disorders: characteristics of an international cohort of 70 patients.

E Poullot, R Zambello, F Leblanc, B Bareau, E De March, M Roussel, M L Boulland, R Houot, A Renault, T Fest and 3 more

Open access · bronzeAbstract readMulticenter Study
In one paragraph

Article in Annals of oncology : official journal of the European Society for Medical Oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 66 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 3 countries.

E PoullotDepartment of Clinical Hematology, Rennes University Hospital, Rennes, France; Department of Pathology, Rennes University Hospital, Rennes, France.
R ZambelloDepartment of Medicine, Hematology and Clinical Immunology Branch, Padua University School of Medicine, Padua, Italy.
F LeblancUniversity of Virginia Cancer Center, University of Virginia School of Medicine, Charlottesville, USA.
B BareauDepartment of Clinical Hematology, Clinique Cesson-Sévigné, Cesson-Sévigné.
E De MarchDepartment of Medicine, Hematology and Clinical Immunology Branch, Padua University School of Medicine, Padua, Italy.
M RousselDepartment of Hematology-Immunology and Cell Therapy, Rennes University Hospital, Rennes; INSERM UMR 917 Faculté de médecine Université Rennes 1, Rennes.
M L BoullandDepartment of Hematology-Immunology and Cell Therapy, Rennes University Hospital, Rennes.
R HouotDepartment of Clinical Hematology, Rennes University Hospital, Rennes, France; INSERM UMR 917 Faculté de médecine Université Rennes 1, Rennes.
A RenaultDepartment of Clinical Investigation, Rennes University Hospital, Rennes, France.
T FestDepartment of Clinical Hematology, Clinique Cesson-Sévigné, Cesson-Sévigné; INSERM UMR 917 Faculté de médecine Université Rennes 1, Rennes.
G SemenzatoDepartment of Medicine, Hematology and Clinical Immunology Branch, Padua University School of Medicine, Padua, Italy.
T LoughranUniversity of Virginia Cancer Center, University of Virginia School of Medicine, Charlottesville, USA.
T LamyDepartment of Clinical Hematology, Rennes University Hospital, Rennes, France; INSERM UMR 917 Faculté de médecine Université Rennes 1, Rennes; Department of Clinical Investigation, Rennes University Hospital, Rennes, France. Electronic address: thierry.lamy@univ-rennes1.fr.
Inserm · FRUniversity of Padua · ITCentre Hospitalier Universitaire de Rennes · FRUniversity of Virginia Cancer CenterTDF (France) · FRUniversité Rennes 2 · FR

Funding

Survival Mechanisms in Leukemic NK CellsR01CA098472 · NCI · UNIVERSITY OF VIRGINIA · PI LOUGHRAN, THOMAS P. · 2003 to 2016
$4.0M
NCI NIH HHS CA094872NCI NIH HHS R01 CA098472
6 · The paper itself

Abstract

backgroundThe 2008 World Health Organization (WHO) classification distinguishes three entities among the large granular lymphocytic leukemia (LGL leukemia): T-cell LGL leukemia (T-LGL leukemia), aggressive natural killer (NK) cell leukemia, and chronic NK lymphoproliferative disorders (LPD), the later considered as a provisional entity. Only a few and small cohorts of chronic NK LPD have been published. PATIENTS AND

methodsWe report here clinicobiological features collected retrospectively from 70 cases of chronic NK LPD, and compared with those of T-LGL leukemia.

resultsThere were no statistical differences between chronic NK LPD and T-LGL leukemia concerning median age [61 years (range 23-82 years)], organomegaly (26%), associated autoimmune diseases (24%), and associated hematological malignancies (11%). Patients with chronic NK LPD were significantly less symptomatic (49% versus 18%, P < 0.001) and the association with rheumatoid arthritis was more rarely observed (7% versus 17%, P = 0.03). The neutropenia (<0.5 × 10(9)/l) was less severe in chronic NK LPD (33% versus 61%, P < 0.001) without difference in the rate of recurrent infections. STAT3 mutation was detected in 12% of the cohort, which is lower than the frequency observed in T-LGL leukemia. Thirty-seven percent of the patients required specific therapy. Good results were obtained with cyclophosphamide. Overall and complete response rates were, respectively, 69% and 56%. Overall survival was 94% at 5 years.

conclusionThis study suggests very high similarities between chronic NK LPD and T-LGL leukemias. Since chronic NK LPD is still a provisional entity, our findings should be helpful when considering further revisions of the WHO classification.

Indexed as

AdultAgedAged, 80 and overFemaleHumansKiller Cells, NaturalLeukemia, Large Granular LymphocyticLymphoproliferative DisordersMaleMiddle AgedRetrospective StudiesSTAT3 Transcription FactorWorld Health OrganizationSTAT3 protein, humanSTAT3 Transcription Factorlarge granular lymphocytic/pathologyleukemianatural killer cells

Identifiers

PMID25096606
PMCPMC4176455
OpenAlexW2149559588

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.